Marksans Pharma Q3FY22 PAT at Rs. 48.27 crore
News

Marksans Pharma Q3FY22 PAT at Rs. 48.27 crore

Marksans Pharma has reported consolidated financial results for the period ended December 31, 2021

  • By IPP Bureau | February 11, 2022

Financial Results (Q3 FY2022) - QoQ comparison

The company has reported a total income of Rs. 374.690 crore during the period ended December 31, 2021 as compared to Rs. 369.768 crore during the period ended September 30, 2021.

The company has posted net profit of Rs. 48.272 crore for the period ended December 31, 2021 as against a net profit of Rs. 46.288 crore for the period ended September 30, 2021.

Financial Results (Q3 FY2022) - YoY comparison

The company has reported a total income of Rs. 374.690 crore during the period ended December 31, 2021 as compared to Rs.355.195 crore during the period ended December 31, 2020.

The company has posted a net profit of Rs.48.272 crore for the period ended December 31, 2021 as against a net profit of Rs.58.940 crore for the period ended December 31, 2020.

Financial Results (nine-month ended FY2022) - YoY comparison

The company has reported a total income of Rs.1099.304 crore during the nine-month period ended December 31, 2021 as compared to Rs.1046.667 crore during the nine-month period ended December 31, 2020.

The company has posted a net profit of Rs.157.162 crore for the nine-month period ended December 31, 2021 as against a net profit of Rs.159.039 crore for the nine-month period ended December 31, 2020.

Upcoming E-conference

Other Related stories

Startup

Digitization